The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of July 31, 2017:
- 46 negotiations are currently underway with 7 new files added since the last update of June 30, 2017:
- Cinqair (reslizumab): Used to treat severe eosinophilic asthma
- Giotrif (afatinib): Used to treat advanced non-small cell lung cancer
- Humira (adalimumab): Used to treat hidradenitis suppurativa
- Kevzara (sarilumab): Used to treat rheumatoid arthritis
- Methadose (methadone): Used to treat opioid dependence
- Trulicity (dulaglutide): Used to treat type 2 diabetes mellitus
- Zykadia (ceritinib): Used to treat ALK+ non-small cell lung cancer
- 163 joint negotiations have been completed with 3 files successfully negotiated since the last update of June 30, 2017:
- Basaglar (insulin glargine): Used to treat type 1 and 2 diabetes mellitus
- Mifegymiso (mifepristone/misoprostol): Used for the medical termination of pregnancy
- Votrient (pazopanib): Used to treat metastatic renal cell carcinoma
- 53 drug products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level with 3 new files added since the last update of June 30, 2017:
- Alecensaro (alectinib): Used to treat non-small cell lung cancer (with CNS metastases)
- Cortiment (budesonide): Use to treat ulcerative colitis
- Viacoram (perindopril/amlodipine): Used to treat hypertension
Please Note: Negotiations involving Viacoram were closed as an agreement was not reached.
- 13 negotiations for brand name drug products have been recommended by the pCPA to be considered by each Province/Territory individually with no new files added since the last update of June 30, 2017.
For more information, please consult the pCPA’s website.